Switch theme
Sign up to access all valuation multiples
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women’s Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.
2015
51
LTM Revenue $26.2M
LTM EBITDA -$12.4M
$81.7M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Elutia has a last 12-month revenue (LTM) of $26.2M and a last 12-month EBITDA of -$12.4M.
In the most recent fiscal year, Elutia achieved revenue of $24.4M and an EBITDA of -$45.9M.
Elutia expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Elutia valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $26.2M | XXX | $24.4M | XXX | XXX | XXX |
| Gross Profit | $11.7M | XXX | $10.7M | XXX | XXX | XXX |
| Gross Margin | 45% | XXX | 44% | XXX | XXX | XXX |
| EBITDA | -$12.4M | XXX | -$45.9M | XXX | XXX | XXX |
| EBITDA Margin | -47% | XXX | -188% | XXX | XXX | XXX |
| EBIT | -$30.9M | XXX | -$24.3M | XXX | XXX | XXX |
| EBIT Margin | -118% | XXX | -100% | XXX | XXX | XXX |
| Net Profit | -$42.8M | XXX | -$53.9M | XXX | XXX | XXX |
| Net Margin | -164% | XXX | -221% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $10.6M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Elutia's stock price is $2.
Elutia has current market cap of $74.0M, and EV of $81.7M.
See Elutia trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $81.7M | $74.0M | XXX | XXX | XXX | XXX | $-1.36 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Elutia has market cap of $74.0M and EV of $81.7M.
Elutia's trades at 3.4x EV/Revenue multiple, and -1.8x EV/EBITDA.
Equity research analysts estimate Elutia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Elutia has a P/E ratio of -1.7x.
See valuation multiples for Elutia and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $74.0M | XXX | $74.0M | XXX | XXX | XXX |
| EV (current) | $81.7M | XXX | $81.7M | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 3.4x | XXX | XXX | XXX |
| EV/EBITDA | -6.6x | XXX | -1.8x | XXX | XXX | XXX |
| EV/EBIT | -2.6x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | 7.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -1.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -3.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialElutia's last 12 month revenue growth is 49%
Elutia's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $0.7M for the same period.
Elutia's rule of 40 is -79% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Elutia's rule of X is 74% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Elutia and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 49% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | -47% | XXX | -188% | XXX | XXX | XXX |
| EBITDA Growth | -10% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -79% | XXX | -140% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 74% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 16% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 144% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Elutia acquired XXX companies to date.
Last acquisition by Elutia was XXXXXXXX, XXXXX XXXXX XXXXXX . Elutia acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Elutia founded? | Elutia was founded in 2015. |
| Where is Elutia headquartered? | Elutia is headquartered in United States of America. |
| How many employees does Elutia have? | As of today, Elutia has 51 employees. |
| Who is the CEO of Elutia? | Elutia's CEO is Dr. C. Randal Mills, PhD. |
| Is Elutia publicy listed? | Yes, Elutia is a public company listed on NAS. |
| What is the stock symbol of Elutia? | Elutia trades under ELUT ticker. |
| When did Elutia go public? | Elutia went public in 2020. |
| Who are competitors of Elutia? | Similar companies to Elutia include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Elutia? | Elutia's current market cap is $74.0M |
| What is the current revenue of Elutia? | Elutia's last 12 months revenue is $26.2M. |
| What is the current revenue growth of Elutia? | Elutia revenue growth (NTM/LTM) is 49%. |
| What is the current EV/Revenue multiple of Elutia? | Current revenue multiple of Elutia is 3.1x. |
| Is Elutia profitable? | Yes, Elutia is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Elutia? | Elutia's last 12 months EBITDA is -$12.4M. |
| What is Elutia's EBITDA margin? | Elutia's last 12 months EBITDA margin is -47%. |
| What is the current EV/EBITDA multiple of Elutia? | Current EBITDA multiple of Elutia is -6.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
